Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366188 | 0.83 | KCNH2 (0.36) | DGAT1PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL2575194 | 0.82 | CHEK1 (0.34) | DGAT1PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL2564359 | 0.81 | DGAT1 (0.34) | DGAT1PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL31039246 | 0.77 | DGAT1 (0.43) | DGAT1KCNH2 | |
| SCHEMBL25629841 | 0.77 | LRRK2 (0.37) | KCNH2 | |
| SCHEMBL3635220 | 0.75 | KCNH2 (0.37) | DGAT1PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL19398631 | 0.74 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL18985815 | 0.74 | PIK3CD (0.38) | DGAT1PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL5928297 | 0.74 | MEN1 (0.39) | DGAT1KLKB1 | |
| SCHEMBL25511617 | 0.73 | JAK2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558468-B1 | 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8962596-B2 | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | ARRAY BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2766368-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | Array Biopharma Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013055645-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2558468-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | Array Biopharma, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130146-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | DGAT1 4642/4885KLKB1 1953/4885PIK3CD 159/4885 |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | JAK1, JAK3, JAK2 | DGAT1 4721/4885KLKB1 1757/4885PIK3CD 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.